The partnership will give Chugai access to Gero’s artificial intelligence technology to discover novel targets in ...

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Despite rehiring hundreds of FDA, CDC and NIH employees, the Department of Health and Human Services is still a skeleton of ...

Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical ...

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

The safety update for Vyvgart rattled argenx’s shares on Monday, a reaction that analysts at William Blair said was “overdone ...

Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to ...

Bioinformatics is on the rise, forecasted to grow by about $16 billion from 2024 to 2029 given its value to managing mass ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...